SEC Form 4 · accession 0001140361-15-002937
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter David Suzdak
Officer — Chief Executive Officer · Director
Period of report
Jan 23, 2015
Accepted (ET)
Jan 27, 2015 · 6:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to purchase)F1 | $0.71 | Jan 23, 2015 | A | 1,100,000 | A | — | Jan 23, 2025 | Common Stock | 1,100,000 | 1,100,000 | D |
Explanation of responses
- F1Options will vest and be exercisable based on the following schedule: 275,000 on January 23, 2016, 275,000 on January 23, 2017, 275,000 on January 23, 2018, and 275,000 on January 23, 2019.